Page 116 - 南京医科大学自然版

第46卷第7期
·1062 · 南 京 医 科 大 学 学 报 2026年7月

瘤患者，靶向联合免疫治疗可作为潜在的辅助治疗 cer：biology，resistance mechanisms，and emerging thera⁃
选择。未来需开展更大规模的前瞻性研究，优化治 peutic strategies［J］. Cancers，2026，18（3）：531
疗策略，更精准地筛选可能获益的人群。 ［9］ BARBE⁃RICHAUD J B，MOINARD⁃BUTOT F，COTTON
利益冲突声明： M，et al. Outcome of metastatic biliary tract cancer har⁃
所有作者声明无利益冲突。 bouring IDH1 or FGFR2 alterations：a retrospective obser⁃
Conflict of Interests： vational real⁃world study from a French cohort［J］. J Clin
Med，2025，14（19）：6759
All authors declare no conflict of interests.
作者贡献声明： ［10］MIE T，SASAKI T，OKAMOTO T，et al. Current status of
张寅祺负责数据分析和论文撰写，兰欣协助整合诊疗资 targeted therapy for biliary tract cancer in the era of preci⁃
料和论文修改，韩国勇、孔连宝和吴金道参与患者整个诊疗过 sion medicine［J］. Cancers，2024，16（5）：879
程，吴金道负责论文选题，审核稿件，协调沟通及对外联络。 ［11］CHI Y，SHU Y Q，BA Y，et al. Anlotinib monotherapy for
refractory metastatic colorectal cancer：a double⁃blinded，
Author’s Contributions：
placebo ⁃ controlled， randomized phase Ⅲ trial
ZHANG Yinqi was in charge of data analysis and
（ALTER0703）［J］. Oncologist，2021，26（10）：e1693-
manuscript writing. LAN Xin helped integrate diagnosis and
e1703
treatment data，and manuscript revision . HAN Guoyong，KONG
［12］LI J J，ZHOU S R，XU X Q，et al. Sintilimab and anlotinib
Lianbao，and WU Jindao participated in the patients’diagnosis
with gemcitabine plus cisplatin in advanced biliary tract
and treatment. WU Jindao contributed to topic selection，reviewed
cancer：SAGC a randomized phase 2 trial［J］. Nat Com⁃
the manuscript，handled coordination and liaison.
mun，2025，16：5559
［参考文献］
［13］LOU Y D，CHEN Y J，GUO K B，et al. Emerging biomark⁃
［1］ RIMASSA L，KHAN S，GROOT K B，et al. Mapping the ers for immunotherapy response in biliary tract cancers：a
landscape of biliary tract cancer in Europe：challenges comprehensive review of immune checkpoint inhibitor
and controversies［J］. Lancet Reg Health Eur，2025，50： strategies［J］. Biomark Med，2024，18（15/16）：703-715
101171 ［14］YUE S W，ZHANG Y P，ZHANG W. Recent advances in
［2］ SHIBATA Y，JANSSON H，KOBAYASHI K，et al. Assess⁃ immunotherapy for advanced biliary tract cancer［J］. Curr
ing surgical resection in recurrent biliary tract cancer：in⁃ Treat Options Oncol，2024，25（8）：1089-1111
ternational two⁃centre experience［J］. Eur J Surg Oncol， ［15］DANPANICHKUL P，NG C H，TAN D J H，et al. The

2026，52（1）：111159 global burden of early⁃onset biliary tract cancer：insight
［3］ PENG Y H，XIA G Y，LI Y F，et al. Postoperative adju⁃ from the global burden of disease study 2019［J］. J Clin
vant chemotherapy and chemoimmunotherapy after radical Exp Hepatol，2024，14（2）：101320
resection for biliary tract cancer：a retrospective study［J］. ［16］SU J，LIANG Y H，HE X F. Global，regional，and national
Oncologist，2025，30（6）：oyaf163 burden and trends analysis of gallbladder and biliary tract
［4］ SAKAMOTO K，UCHIDA Y，KADONO K，et al. Prognos⁃ cancer from 1990 to 2019 and predictions to 2030：a sys⁃
tic impact of additional resection of bile duct margins in tematic analysis for the Global Burden of Disease Study
radical resection for perihilar cholangiocarcinoma［J］. An⁃ 2019［J］. Front Med，2024，11：1384314
ticancer Res，2025，45（11）：5095-5107 ［17］QUEIROZ M M，LIMA N F，BIACHI DE CASTRIA T. Im⁃
［5］ RIZZO A，BRANDI G. BILCAP trial and adjuvant munotherapy and targeted therapy for advanced biliary
capecitabine in resectable biliary tract cancer：reflections tract cancer：adding new flavors to the pizza［J］. Cancers，
on a standard of care［J］. Expert Rev Gastroenterol Hepa⁃ 2023，15（7）：1970
tol，2021，15（5）：483-485 ［18］MAO T H，LI X，WANG L，et al. Efficacy and safety of tar⁃
［6］ PRIMROSE J N，FOX R P，PALMER D H，et al. geted therapy and immune checkpoint inhibitors in pa⁃
Capecitabine compared with observation in resected tients with advanced or metastatic biliary tract cancer：a
biliary tract cancer（BILCAP）：a randomised，controlled， meta⁃analysis of and sequential analysis of trials［J］. Hepa⁃
multicentre，phase 3 study［J］. Lancet Oncol，2019，20 tol Int，2025，19（6）：1412-1427
（5）：663-673 ［19］JIN S L，ZHAO R H，ZHOU C，et al. Feasibility and toler⁃
［7］ GOETZE T O，RODERBURG C，FRIEDRICH F W，et al. ability of sintilimab plus anlotinib as the second⁃line ther⁃
New perspectives in biliary tract cancers［J］. ESMO Gas⁃ apy for patients with advanced biliary tract cancers：an
trointest Oncol，2024，5：100092 open⁃label，single⁃arm，phase Ⅱ clinical trial［J］. Int J
［8］ XIN X，MIAO R Y. FGFR2⁃rearranged biliary tract can⁃ Cancer，2023，152（8）：1648-1658